Skip to main content
XNCR
NASDAQ Life Sciences

Xencor Remediates Material Weaknesses, Reports Strong Partnered Pipeline Progress & Reduced Net Loss

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$11.98
Mkt Cap
$855.497M
52W Low
$6.92
52W High
$18.69
52W Position info
73% above low
Off High info
36% below high
Rel. Volume info
1.0× avg
Market data snapshot near publication time

XNCR sits 73% above its 52-week low of $6.92.

Summary

Xencor announced the full remediation of material weaknesses in internal controls, reported significant progress for partnered clinical programs including a Phase 3 success and planned BLA submission, and a reduced net loss for 2025, while continuing to navigate patent litigation.


Key Events · Corporate Governance and Compliance · XNCR

  • Material Weaknesses Remediation

    Xencor announced the full remediation of previously disclosed material weaknesses in internal control over financial reporting as of December 31, 2025, enhancing financial reporting reliability.

  • Partnered Pipeline Advancement

    Partner Zenas BioPharma reported positive Phase 3 results for obexelimab in IgG4-RD, with a Biologics License Application (BLA) submission anticipated in Q2 2026. Additionally, Amgen initiated a Phase 3 study for xaluritamig in metastatic castration-resistant prostate cancer.

  • Reduced Net Loss

    The company reported a net loss of $91.9 million for 2025, a significant improvement from the $232.6 million net loss in 2024, partly driven by $101.5 million in gains on marketable equity securities.

  • Ongoing Patent Litigation

    Xencor is actively defending against a patent infringement lawsuit filed by Merus N.V., with a hearing on a motion to dismiss an amended complaint held in February 2026 and *inter partes* review granted for certain patents.


Analysis · XNCR · Life Sciences

This 10-K filing highlights significant positive developments for Xencor. The full remediation of previously disclosed material weaknesses in internal control over financial reporting is a crucial step in strengthening corporate governance and investor confidence. Furthermore, the advancement of partnered assets, particularly Zenas BioPharma's obexelimab with positive Phase 3 results and a planned BLA submission, and Amgen's initiation of a Phase 3 study for xaluritamig, validates Xencor's technology platform and signals potential future royalty streams. While the ongoing patent litigation with Merus N.V. presents a material risk, the company is actively defending its position. The substantial reduction in net loss and a cash runway through 2028 provide a more stable financial outlook for the clinical-stage biopharmaceutical company.

How filings like this one have moved

In the 30 days to Nov 8, 2026, 46.6% of the 1552 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.23%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, XNCR was trading at $11.98 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $855.5M. The 52-week trading range was $6.92 to $18.69. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

XNCR - Latest Insights

XNCR
Nov 04, 2026, 4:02 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $36.00
Real-time Price: $35.82 info
Change: -$0.1799 (-0.50%) info
Market Cap: $2.658B info
XNCR
Nov 04, 2026, 4:01 PM EST
Source: BusinessWire
Importance Score:
7
Price at Filing: $34.98
Real-time Price: $35.82 info
Change: +$0.8451 (+2%) info
Market Cap: $2.658B info
XNCR
Oct 26, 2026, 1:00 PM EDT
Source: Benzinga
Importance Score:
7
Price at Filing: $30.18
Real-time Price: $35.82 info
Change: +$5.65 (+19%) info
Market Cap: $2.658B info
XNCR
Oct 26, 2026, 7:50 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $34.02
Real-time Price: $35.82 info
Change: +$1.80 (+5%) info
Market Cap: $2.658B info
XNCR
Oct 25, 2026, 4:35 AM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $25.55
Real-time Price: $35.82 info
Change: +$10.27 (+40%) info
Market Cap: $2.658B info